Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39th Annual Strategic Decisions Conference on May 31st at the New York Hilton Midtown. Joaquin Duato, Chairman of the Board and CEO, will represent the company in a session scheduled for 10:00 a.m. (Eastern Time).
This event will be accessible to investors and interested parties via the Johnson & Johnson website at www.investor.jnj.com. A replay of the webcast will be available approximately 48 hours after the live session.
Johnson & Johnson (NYSE: JNJ) has announced the launch of a roadshow for the initial public offering (IPO) of its subsidiary, Kenvue Inc., offering 151,204,000 shares at an expected price of $20.00 to $23.00 per share. The underwriters will have a 30-day option to purchase an extra 22,680,600 shares. After the IPO, JNJ will hold 91.9% of Kenvue's shares. Goldman Sachs, J.P. Morgan, and BofA Securities are leading the IPO, with a registration statement filed with the SEC that is not yet effective. The press release emphasizes the commitment of JNJ to health and wellness, along with a cautionary note on forward-looking statements regarding the IPO and economic factors impacting Kenvue's success as a standalone company.
Lawyers for around 55,000 plaintiffs in the lawsuit against Johnson & Johnson (JNJ) over cancer-linked talcum powder have formed an Ad Hoc Committee. They support an $8.9 billion settlement aimed at resolving a lengthy legal battle. LTL Management, a J&J subsidiary, is again filing for Chapter 11 bankruptcy to create a trust for compensating affected victims.
The proposed settlement includes removing all talc-based products globally and ensuring compensation for current claimants within a year. The Ad Hoc Committee, which has retained bankruptcy counsel, needs a 75% claimant approval for the settlement to pass. This follows scientific evidence linking J&J's products to serious health issues, as well as previous bankruptcy attempts that were rejected by the courts.
Johnson & Johnson (JNJ) reported a 5.6% increase in first-quarter 2023 sales, reaching $24.7 billion. The operational growth was 9.0%*, with adjusted operational growth at 7.6%*. The basic loss per share was ($0.03), showing a 101.6% decrease due to a one-time charge, while adjusted earnings per share (EPS) rose 0.4%* to $2.68. The company is increasing its 2023 full-year guidance for adjusted operational sales and EPS. Key segment performances included Consumer Health, up 11.3%*, Pharmaceuticals, up 7.2%*, and MedTech, with a 6.4%* increase. Positive developments included CHMP opinion for AKEEGA and promising results for CARVYKTI and Nipocalimab studies.
Johnson & Johnson (NYSE: JNJ) has reached a resolution involving a total payout of $12.08 billion to compensate around 65,000 plaintiffs affected by cancer linked to its talcum powder products. This agreement includes an initial $8.9 billion into a bankruptcy trust to support current and future victims. JNJ's history of concealing product risks has led to legal battles, culminating in a recent court ruling against its previous bankruptcy filing. Under the new terms, JNJ aims to have all current claimants paid within one year, while committing to remove talc-based products globally.
Johnson & Johnson has announced the re-filing of its subsidiary LTL Management LLC for voluntary Chapter 11 bankruptcy protection. This move aims to secure approval for a revised reorganization plan to resolve all claims related to cosmetic talc litigation with a present value commitment of
Virtual Incision Corporation has appointed Piet Hinoul as the new Chief Medical Officer, while Dmitry Oleynikov transitions to Chief Surgeon. Hinoul, with over 30 years in healthcare, previously headed medical affairs at Novocure (NASDAQ: NVCR) and has experience in surgical robotics at Johnson & Johnson (NYSE: JNJ). This leadership change aims to bolster Virtual Incision's efforts as it develops the MIRA Surgical System, the first miniaturized robotic-assisted surgery system designed for improved surgical efficiency. The company is focused on making every operating room RAS-ready, enhancing accessibility to advanced surgical technology.
The Third Circuit Court has denied a rehearing request regarding Johnson & Johnson's (NYSE:JNJ) bankruptcy petition related to talcum powder litigation, determining it was not filed in good faith. This decision enables over 38,000 lawsuits alleging links between J&J's talc products and cancer to resume. The court found that J&J's use of the Texas Two-Step bankruptcy strategy to limit claims was not justified and indicated that LTL, its subsidiary, was not in financial distress. The firm plans to cease production of talc-based products globally amid ongoing litigation and regulatory scrutiny over the potential carcinogenic effects of talc.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
